Fenofibrate

Indications

• • Hypercholesterolemia

  • Reduction of cholesterol levels in patients at risk of cardiovascular disease

• hypertriglyceridemia

Administration/Absorption

Distribution

Mechanism

• fibrate class

• Effects via activation of Peroxisome Proliferator Activated Receptor type alpha (PPARα)

  • Increases the lipolysis and elimination of atherogenic triglyceride-rich particles from plasma by

    • activating lipoprotein lipase

    • reducing production of apoprotein CIII.

  • Also induces an increase in the synthesis of apoproteins AI and AII

    • leads to a reduction in very low - and low density fractions (VLDL and LDL) containing apoprotein B

    • and an increase in the high density lipoprotein fraction (HDL) containing apoprotein AI and AII.

• Increases LDL clearance and reduces small and dense LDL

Excretion